The Immunopathology Group part of a European consortium developing cellular immunotherapies
The official kick-off meeting of the consortium INsTRuCT (INnovative Training in myeloid Regulatory Cell Therapy) took place this week in Regensburg, Germany and Dr Eva Martínez-Cáceres, Head of the Immunopathology Research Group, took part. InsTRuCT is a Marie Skłodowska-Curie Action, within the Horizon 2020 research funding programme. Its members are European researchers from the areas of academia and business and their aim is to carry out basic and clinical research to develop immunotherapies based on myeloid regulatory cells (MRC).
As a training programme INsTRuCT offers a total of 15 pre-doctoral research projects in 13 institutions in Europe, covering a wide range of research from the most basic to more translational clinical studies. During the training, the selected doctoral students will be trained and gain first-hand experience from expert professionals in basic immunology research, pre-clinical drug development, manufacturing processes of cell products, clinical trial design, health economics and marketing.
The group led by Dr Eva Martínez-Cáceres at the IGTP offers a project in translational clinical research. The team of Dr Eva Martínez-Cáceres and Dr Cristina Ramo Tello have developed a cell therapy to treat multiple sclerosis called tolDC-VitD3. The treatment is currently in a phase I clinical trial ((EUDRA CT 2015-003541-26) to scale dosage. The project offered in the context of INsRTuCT looks at aspects of the biology and pharmacodynamics effects of therapy with tolDC-VitD3 in patients participating in the current trial.
The final date to apply for the projects is 31 January, after which the selection process will start in two phases. You can consult information about the consortium, the projects and the selection process on the INsTRuCT web, or the vacancies page on EURAXESS.